Boltz vs GE HealthCare
Side-by-side comparison of AI visibility scores, market position, and capabilities
Open-source AI for biomolecular structure prediction. $28M seed from a16z. Pfizer collaboration. Boltz-2 rivals physics methods at 1000x speed. MIT spinout.
About
Boltz was founded as a spinout from MIT with a mission to democratize access to AI-driven biomolecular structure prediction. The company was inspired by the transformative impact of AlphaFold on structural biology and sought to build the next generation of prediction systems that could go beyond protein structure to model the full complexity of biomolecular interactions, including protein-ligand binding, RNA folding, and multi-chain assemblies. By releasing its models as open source, Boltz made frontier-grade structural biology tools available to any researcher with a computer.\n\nBoltz-2, the company's latest model, rivals physics-based molecular dynamics simulations in accuracy while operating at approximately 1,000 times the speed, compressing computational experiments that once required weeks into hours or minutes. This performance profile makes Boltz-2 practical for drug discovery workflows where structural predictions must be generated across millions of candidate molecules. Boltz entered a collaboration with Pfizer, one of the world's largest pharmaceutical companies, to apply its models to drug discovery programs — a validation of both the technology's accuracy and its readiness for industrial-scale deployment.\n\nBoltz raised a $28 million seed round led by Andreessen Horowitz's bio fund, reflecting a16z's conviction that open-source biomolecular AI represents a foundational layer of the next generation of drug discovery infrastructure. The open-source strategy gives Boltz broad academic adoption and a rich pipeline of community feedback that accelerates model improvement. Its MIT lineage, Pfizer partnership, and a16z backing position Boltz as a leading independent AI platform in the computational biology space.
Chicago medical imaging and AI diagnostics (NASDAQ: GEHC) ~$19.7B FY2024 revenue; GE spinoff Jan 2023, Edison AI 100+ models, 4M+ installed devices, Alzheimer's PET tracer competing with Siemens Healthineers.
About
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designing, manufacturing, and servicing medical imaging systems, patient monitoring equipment, pharmaceutical diagnostics, and AI-powered clinical decision support software through approximately 51,000 employees in 160 countries. GE HealthCare was spun off from General Electric Company in January 2023 — one of the most significant healthcare demergers in history — and has operated as an independent public company building its own capital structure, R&D investment priorities, and operational identity separate from GE's industrial conglomerate structure. In fiscal year 2024, GE HealthCare reported revenues of approximately $19.7 billion, with its four business segments contributing: Imaging (MRI, CT, X-ray, molecular imaging — ~$9.1B), Ultrasound (~$3.0B), Patient Care Solutions (monitoring, anesthesia — ~$3.6B), and Pharmaceutical Diagnostics (PET/SPECT contrast agents — ~$2.6B). CEO Peter Arduini has prioritized accelerating GE HealthCare's AI integration across its imaging portfolio — the Edison AI platform (100+ AI models cleared or in development for radiology workflows) embeds AI-assisted detection, workflow optimization, and image quality enhancement into GE HealthCare scanners, positioning the company as a digital health platform rather than a hardware manufacturer.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.